Drug repurposing of antidiabetic agents against COVID-19’s 3CLpro enzyme | ||||
| Journal of Pharmaceutical Sciences and Drug Manufacturing-Misr University for Science and Technology | ||||
| Volume 2, Issue 2 - Serial Number 20225, June 2025, Page 1-12 PDF (734.36 K) | ||||
| Document Type: Research articles | ||||
| DOI: 10.21608/jpsdm.2025.338507.1026 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Heba S. Rateb; Ahmed M. Nonn; Omar K. Bakr; Lina M. Amin 
| ||||
| Pharmaceutical Chemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Egypt. | ||||
| Abstract | ||||
| Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was the etiological agent responsible for the 2019-2020 viral pneumonia outbreak of coronavirus disease, in such a pandemic, it is important to utilize time-saving strategies like drug repurposing, which saves time and money. Objective: To repurpose antidiabetic agent(s) that can combat SARS-COV-2, which could benefit diabetic patients infected with the virus while saving the time and money needed for the discovery of novel agents. Methods: In the present study, 23 antidiabetic drugs were docked against the active site of SARS-CoV-2 3CL Pro (PDB ID: 7WOF) using BIOVIA Discovery Studio (BIOVIA DS) software, to investigate the inhibitory activity of tested antidiabetic drugs. Results: Gliflumide revealed higher activity than the co-crystalized ligand, 5IZ (-45.78 kcal/mol), with CDOCKER values of (-46.58 kcal/mol). Glicetanile and Gliquidone revealed CDOCKER values of (-41.09 and -40.16 kal/mol respectively). Gliflumide seems to have the potential to be a promising ligand against SARS-CoV-2, and thus it requires further validation by in vitro studies. | ||||
| Keywords | ||||
| SAR-COV-2; Drug Repositioning; Diabetes; Protease; Inflammation | ||||
|
Statistics Article View: 85 PDF Download: 25 |
||||
